107735-20-6

Basic information

• Product Name: Magnesium, chloro[(dimethylphenylsilyl)methyl]-
• CAS NO: 107735-20-6
• Molecular Formula: C9H13ClMgSi
• Molecular Weight: 209.046
• Mol File: 107735-20-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Magnesium, chloro[(dimethylphenylsilyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Magnesium, chloro[(dimethylphenylsilyl)methyl]-(107735-20-6)
• EPA Substance Registry System: Magnesium, chloro[(dimethylphenylsilyl)methyl]-(107735-20-6)

Safety Data

• Hazardous Substances Data: 107735-20-6(Hazardous Substances Data)

Upstream product

• 1833-51-8 chloromethyldimethylphenylsilane 
• 7439-95-4 magnesium 

Downstream Products

• 13950-56-6 ethyl [2-(dimethylphenyl)silyl]ethanoate 
• 145296-86-2 C₂₈H₃₈Si₃ 
• 152574-30-6 7-Deoxy-1,2:3,4-di-O-isopropylidene-7-(phenyldimethylsilyl)-D-glycero-α-D-galacto-heptopyranose 
• 122588-55-0 methyl-2,3,4-tri-O-benzyl-7-(Si-dimethylphenyl-silyl)-L-glycero-α-Dmanno-heptopyranoside 
• 142981-41-7 C₂₁H₂₈Si₂ 
• 126412-70-2 methyl 3-O-allyl-2,4-di-O-benzyl-7-(phenyldimethylsilyl)-7-deoxy-L-glycero-α-D-manno-heptopyranoside 
• 123149-77-9 (R)-1-((2R,3S,4S,5S,6S)-4,6-Bis-allyloxy-3,5-bis-benzyloxy-tetrahydro-pyran-2-yl)-2-(dimethyl-phenyl-silanyl)-ethanol 
• 123149-77-9 (S)-1-((2R,3S,4S,5S,6S)-4,6-Bis-allyloxy-3,5-bis-benzyloxy-tetrahydro-pyran-2-yl)-2-(dimethyl-phenyl-silanyl)-ethanol 
• 126412-70-2 (S)-1-((2R,3S,4S,5S,6S)-4-Allyloxy-3,5-bis-benzyloxy-6-methoxy-tetrahydro-pyran-2-yl)-2-(dimethyl-phenyl-silanyl)-ethanol 
• 120627-96-5 1-(dimethyl-phenyl-silanyl)-but-3-en-2-ol 
• 156551-17-6 1-(dimethylphenylsilylmethyl)-1,9-dihydro(C₆₀-I_h)[5,6]fullerene 
• 161377-12-4 Benzyl-[(R)-2-(dimethyl-phenyl-silanyl)-1-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyl-tetrahydro-bis[1,3]dioxolo[4,5-b;4',5'-d]pyran-5-yl)-ethyl]-amine 

Relevant articles and documents

Enantioselective total syntheses of citrinadins A and B. Stereochemical revision of their assigned structures

The concise, enantioselective total syntheses of (-)-citrinadin A and (+)-citrinadin B in a total of only 20 and 21 steps, respectively, from commercially available starting materials are described. Our strategy, which minimizes refunctionalization and protection/deprotection operations, features the highly diastereoselective, vinylogous Mannich addition of a dienolate to a chiral pyridinium salt to set the first chiral center. The absolute stereochemistry of this key center was then relayed by a sequence of substrate-controlled reactions, including a highly stereoselective epoxidation/ring opening sequence and an oxidative rearrangement of an indole to furnish a spirooxindole to establish the remaining stereocenters in the pentacyclic core of the citrinadins. An early stage intermediate in the synthesis of (-)-citrinadin A was deoxygenated to generate a dehydroxy compound that was elaborated into (+)-citrinadin B by a sequence of reaction identical to those used to prepare (-)-citrinadin A. These concise syntheses of (-)-citrinadin A and (+)-citrinadin B led to a revision of their stereochemical structures.